Cell processing
Reported revenue in 2020 ¥682.83M Reported revenue in 2024 ¥810.07M
- growth amount
- +¥127.25M
- growth annualized
- +4.4%
- growth total
- +18.6%
Japanese company profile · 2370
MEDINET Co., Ltd.
In its FY2024 public filing, MEDINET Co., Ltd. reports Cell processing, Regenerative Medicine Products Business. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 株式会社メディネット
English company name recorded in Japan's EDINET filer data. English company name source
What does this company do?
What does this company do?
MEDINET Co., Ltd.'s largest reported business by revenue in FY2024 was Cell processing.
FY2024 · fiscal year ended September 2025 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Sales | Revenue share | Operating profit |
|---|---|---|---|
| Cell processing | ¥810.07M ↗ | — | −¥474.86M ↗ |
| Regenerative Medicine Products Business | ¥219,000 ↗ | — | −¥407.98M ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2024 · fiscal year ended September 2025. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Cell processing
- 細胞加工業
- Regenerative Medicine Products Business
- 再生医療等製品事業
- Sales
- 売上高
- Operating profit
- 営業利益
Original Japanese label
- Cell processing
- 細胞加工業
- Regenerative Medicine Products Business
- 再生医療等製品事業
- Sales
- 売上高
- Operating profit
- 営業利益
Reported Sales by business over time
Reported Sales by business over time
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Cell processing | ¥682.83M | ¥633.45M | ¥661.08M | ¥768.25M | ¥810.07M |
| Regenerative Medicine Products Business | ¥206,000 | ¥221,000 | ¥467,000 | ¥245,000 | ¥219,000 |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2024 · fiscal year ended September 2025
The source document may be in Japanese.
Filing ID: S100XB0H
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.